News about Global Pharma

Thetis Pharmaceuticals Receives Additional USD 8.975 Million in Program-Related Investment Funds to Advance TP-317

The newly approved funding will support a Phase 1b trial of TP-317 in ulcerative colitis patients to identify safe and efficient dosing.

Global Pharma | 13/01/2025 | By Aishwarya |  400

Gilead and LEO Pharma to Advance Development of Oral STAT6 Program

STAT6 is the specific transcription factor required for IL-4 and IL-13 cytokine signaling, which are clinically validated targets for Th2 mediated inflammatory conditions such as atopic dermatitis, asthma, and COPD, amongst many others.

Global Pharma | 13/01/2025 | By Aishwarya |  258

Sciwind Signs Global Licensing Deal with Verdiva for Metabolic Disease Portfolio

Sciwind has granted Verdiva the exclusive global rights to develop, manufacture and commercialize the partnered programs outside of greater China and South Korea.

Global Pharma | 13/01/2025 | By Aishwarya |  504

Windlas Biotech Receives GMP Certification for New Injectable Facility

Windlas Biotech Ltd. has received Good Manufacturing Practices (GMP) certification for its state-of-the-art injectable facility from the Food Safety and Drugs Administration Authority of Uttarakhand.

Global Pharma | 10/01/2025 | By Manvi |  879

SN BioScience Secures IND Clearance from FDA for SNB-101

SN BioScience announced that its lead asset, SNB-101, has received Investigational New Drug (IND) clearance from the US FDA for a Phase 1b/2 clinical trial, marking a significant milestone in its journey toward early commercialisation as a treatment for Extensive Stage Small Cell Lung Cancer (ES-SCLC).

Global Pharma | 10/01/2025 | By Manvi |  630

Ventris Medical's Backpack Bone Graft Systems Secure FDA 510(k) Clearance

Backpack® represents a new class of biomaterials designed for the optimisation of cell proliferation and bone formation and is used in orthopedic and spinal fusion procedures.

Global Pharma | 10/01/2025 | By Abha |  408

American Injectables Secures FDA Approval

American Injectables, specialising in sterile injectables, has announced that it has received FDA approval.

Global Pharma | 10/01/2025 | By Abha |  449

Johnson & Johnson Receives FDA Fast Track Designations for Treatment of Alzheimer's Disease

Posdinemab is the second Fast Track designation granted in 2024 for the Company’s AD portfolio.

Global Pharma | 10/01/2025 | By Aishwarya |  373

Alchemab Therapeutics and Lilly Partner to Develop Novel Therapies for ALS

Alchemab Therapeutics has partnered with Lilly to discover novel therapeutic antibodies for amyotrophic lateral sclerosis (ALS), leveraging Alchemab's platform to identify resilience-associated antibodies in patient samples.

Global Pharma | 09/01/2025 | By Manvi |  277

Lupin Receives EIR from US FDA for Pithampur Unit-1 Facility

Global pharma major Lupin Ltd. has received an EIR with a Voluntary Action Indicated (VAI) classification from the US FDA for its Pithampur Unit-1 manufacturing facility following a September 2024 inspection.

Global Pharma | 09/01/2025 | By Manvi |  489